<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014793</url>
  </required_header>
  <id_info>
    <org_study_id>Mattapr1</org_study_id>
    <nct_id>NCT01014793</nct_id>
  </id_info>
  <brief_title>Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients</brief_title>
  <official_title>Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin
      analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy
      with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This
      study was designed to evaluate short and long term efficacy of cabergoline in controlling
      IGF-I levels in acromegalic patients receiving octreotide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Control of IGF-I levels</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>control IGI-I levels</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Responders to cabergoline</arm_group_label>
    <description>patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabergoline</intervention_name>
    <description>cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal</description>
    <arm_group_label>Responders to cabergoline</arm_group_label>
    <other_name>cabergoline-Dostinex</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum for IGI-I, GH and prolactin measures
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Nineteen acromegalic patients (Neuroendocrine Unit-UNIFESP)with active disease, resistant
        to octreotide were enrolled
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active disease, under octreotide treatment at least 9 months

        Exclusion Criteria:

          -  Cabergoline allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Abucham, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04039030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000 Mar 17;275(11):7862-9.</citation>
    <PMID>10713101</PMID>
  </reference>
  <reference>
    <citation>Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004 Feb;89(2):667-74.</citation>
    <PMID>14764779</PMID>
  </reference>
  <reference>
    <citation>Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 May;94(5):1509-17. doi: 10.1210/jc.2008-2421. Epub 2009 Feb 10. Review.</citation>
    <PMID>19208732</PMID>
  </reference>
  <results_reference>
    <citation>Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15.</citation>
    <PMID>15272916</PMID>
  </results_reference>
  <results_reference>
    <citation>Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005 Apr;152(4):569-74.</citation>
    <PMID>15817912</PMID>
  </results_reference>
  <results_reference>
    <citation>Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998 Feb;83(2):374-8.</citation>
    <PMID>9467544</PMID>
  </results_reference>
  <results_reference>
    <citation>Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000 Apr 7;288(5463):154-7.</citation>
    <PMID>10753124</PMID>
  </results_reference>
  <results_reference>
    <citation>Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology. 2009;90(1):82-92. doi: 10.1159/000218323. Epub 2009 May 8.</citation>
    <PMID>19439914</PMID>
  </results_reference>
  <results_reference>
    <citation>Gatta B, Hau DH, Catargi B, Roger P, Tabarin A. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf). 2005 Oct;63(4):477-8.</citation>
    <PMID>16181243</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Priscilla Olim de Andrade MAttar</name_title>
    <organization>Federal University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Acromegaly resistant</keyword>
  <keyword>combined-treatment</keyword>
  <keyword>dopamine agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

